Here is the design of a clinical trial:

Official Title: Clinical Trial to Estimate the Efficacy, Safety and Cost-utility of the Trapezium-Metacarpal (TMC) Prosthesis Compared to Suspensionplasty.

Included conditions:
- First CarpoMetacarpal Osteoartrithis
- Basal Thumb Osteoartrithis

Study Armgroups:
- {'label': 'Maïa® TMC Prosthesis (Lépine Groupe)', 'type': 'ACTIVE_COMPARATOR', 'description': 'Patients undergoing thumb basal joint arthroplasty using Maïa® TMC prosthesis as treatment of osteoarthritis.', 'interventionNames': ['Procedure: Maïa® TMC Prosthesis (Lépine Groupe)']}
- {'label': 'APL Suspensionplasty', 'type': 'ACTIVE_COMPARATOR', 'description': 'Patients undergoing thumb basal joint arthroplasty using APL Suspensionplasty as treatment of osteoarthritis.', 'interventionNames': ['Procedure: APL Suspensionplasty']}

Interventions:
- {'type': 'PROCEDURE', 'name': 'Maïa® TMC Prosthesis (Lépine Groupe)', 'description': 'Patients undergoing thumb basal joint arthroplasty using Maïa® TMC prosthesis as treatment of osteoarthritis.', 'armGroupLabels': ['Maïa® TMC Prosthesis (Lépine Groupe)']}
- {'type': 'PROCEDURE', 'name': 'APL Suspensionplasty', 'description': 'Patients undergoing thumb basal joint arthroplasty using APL Suspensionplasty as treatment of osteoarthritis.', 'armGroupLabels': ['APL Suspensionplasty']}

Primary Outcomes:
- {'measure': 'Change in Pain, pre- to post-operatively, as measured by a standard visual analogue score (VAS) diagram to grade perceived pain', 'description': 'The standard VAS diagram is a scale from 0 to 10 where 0 indicates No Pain (smiling face), and 10 indicates Worst possible, unbearable, excruciating pain (crying face).', 'timeFrame': 'Baseline, 3 weeks after surgery, 6 weeks after surgery, 3 months after surgery, 6 months, 1 year after surgery, 2 years after surgery'}

Please estimate the sample size based on the assumption: 
Alpha risk of 0.05, beta risk of 0.1, bilateral contrast, common standard deviation of 1.5, and 10% dropout rate.
Sample size
          A total of 106 participants will be necessary (53 subjects for each treatment group) to detect differences equal to or greater than 30% in the visual analog scale (VAS) on the baseline status of the patient [33]. Accepted values will be for an alpha risk of 0.05 and a beta risk of 0.1, in a bilateral contrast. The common standard deviation is assumed to be 1.5. It is assumed that 10% of the trial patients will be lost.